Pancreatic Surgery in Cancer Patients

Post-Surgical Care
  • Kristine McCarthyEmail author
  • Wei ZhangEmail author
  • Jose Soliz
  • Danilo Lovinaria
Reference work entry


Pancreatic cancer, despite its low occurrence, is the tenth leading cause of cancer in the United States, but the fourth leading cause of cancer-related deaths among men and women (Niederhuber et al., Abeloff’s clinical oncology. 5th ed. Philadelphis: Saunders; 2014). Although there is no evidence linking pancreatic cancer to caffeine consumption, cholelithiasis, or diabetes mellitus, its occurrence increased steadily in recent years, possibly due to the increase in the prevalence of obesity, obesity-related health issues, aging population, and other unknown factors. The high mortality rate remains largely unchanged. Ductal adenocarcinoma and its variants account for the most pancreatic malignancies. High-quality imaging preoperatively is important in distinguishing between potential resectable and unresectable diseases. The National Comprehensive Cancer Network (NCCN) established clinical guidelines to assist clinicians in clinical decision-making regarding pancreatic cancer treatment. Those guidelines focus on the diagnosis and the treatment with systemic therapy, radiation therapy, and surgical resection. At a large-volume cancer center, the overall guiding principle in managing pancreatic cancer focuses on well-organized multidisciplinary teams. From multiphase imaging studies, surgery, medical oncology, interventional endoscopy, anesthesiology, dietitian, critical care team, nursing, caregivers, and all teams are critical in successfully managing this disease.


Pancreatic cancer Pancreatic resection Metastatic disease Pancreatic surgery Postoperative Fistula Whipple Pasireotide 


  1. 1.
    AlBalawi Z, Gramlich L, Nelson G, Senior P, Youngson E, McAlister FA. The impact of the implementation of the enhanced recovery after surgery (ERAS®) program in an entire health system: a natural experiment in Alberta, Canada. World J Surg. 2018;42(9):2691–700.CrossRefGoogle Scholar
  2. 2.
    Allen PJ, Gönen M, Brennan MF, Bucknor AA, Robinson LM, Pappas MM, Carlucci KE, D'Angelica MI, DeMatteo RP, Kingham TP, Fong Y, Jarnagin WR. Pasireotide for postoperative pancreatic fistula. N Engl J Med. 2014;370(21):2014–22.CrossRefGoogle Scholar
  3. 3.
    Auklein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. SO Cancer J. 2001;7(4):266.Google Scholar
  4. 4.
    Bose D, Katz MHG, Fleming JB. Pancreatic adenocarcinoma. In: Feig BW, Ching CD, editors. The MD Anderson surgical oncology hand book, vol. 12. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2012. p. 355–67.Google Scholar
  5. 5.
    Buhrman WC, Lyman WB, Kirks RC, Passeri MJ, Vrochides D. Current State of Enhanced Recovery After Surgery in Hepatopancreatobiliary Surgery. J Laparoendosc Adv A. 2018;28(12):1471–1475.CrossRefGoogle Scholar
  6. 6.
    Candido KD, Kusper TM, Knezevic NN. Curr Pain Headache Rep. 2017;21:12. Scholar
  7. 7.
    Elias KM, Stone AB, et al. The reporting on ERAS compliance, outcomes, and elements research checklist: a joint statement by the ERAS and ERAS USA societies. World J Surg. 2018; PMID:30116862
  8. 8.
    Han GJ, Kim S, Lee NK, et al. Prediction of late postoperative hemorrhage after whipple procedure using computed tomography performed during early postoperative period. Korean J Radiol. 2018;19(2):284–91. Scholar
  9. 9.
    Hines R, Marschall K. Stoelting’s anesthesia and co-existing disease. 7th ed. Amsterdam: Elsevier; 2017.Google Scholar
  10. 10.
    Jaffe RA. Anesthesiologist’s manual of surgical procedures. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.Google Scholar
  11. 11.
    Kamisawa T, Wood LD, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
  12. 12.
    Pietri LD, Montalti R, Begliomini BD. Anaesthetic perioperative management of patients with pancreatic cancer. World J Gastroenterol. 2014;209:2304–20.CrossRefGoogle Scholar
  13. 13.
    Lu C, Xu CF, Wan XY, Zhu HT, Yu CH, Li YM. Screening for pancreatic cancer in familial high-risk individuals: a systematic review. World J Gastroenterol. 2015;21(28):8678–86. Scholar
  14. 14.
    Ma L, Dominguez-Rosado I, Gennarelli RL. The cost of postoperative pancreatic fistula versus the cost of pasireotide: results from a prospective randomized trial. Ann Surg. 2017;265(1):11–6.CrossRefGoogle Scholar
  15. 15.
    Maggino L, Liu JB, Ecker BL, Pitt HA, Vollmer CM Jr. Impact of operative time on outcomes after pancreatic resection: a risk-adjusted analysis using the American College of Surgeons NSQIP database. J Am Coll Surg. 2018;18:30035–8.Google Scholar
  16. 16.
    Martin TD, Lorenz T, Ferraro J, Chagin K, Lampman RM, Emery KL, Zurkan JE, Boyd JL, Montgomery K, Lang RE, Vandewarker JF, Cleary RK. Newly implemented enhanced recovery pathway positively impacts hospital length of stay. Surg Endosc. 2016;30(9):4019–28.CrossRefGoogle Scholar
  17. 17.
    Martin LW, Sarosiek BM, Harrison MA, Hedrick T, Isbell JM, Krupnick AS, Lau CL, Mehaffey JH, Thiele RH, Walters DM, Blank RS. Implementing a thoracic enhanced recovery program: lessons learned in the first year. Ann Thorac Surg. 2018;105(6):1597–604.CrossRefGoogle Scholar
  18. 18.
    Nayar P, Chandak A, Gupta N, Yu F, Qiu F, Ganti AK, Are C. Postoperative mortality following multi-modality therapy for pancreatic cancer: analysis of the SEER-Medicare data. J Surg Oncol. 2017;115:158–63. Scholar
  19. 19.
    Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff’s clinical oncology. 5th ed. Philadelphia: Saunders; 2014.Google Scholar
  20. 20.
    Ross Paul J, Bradney M, Simpson J. P-229 PanCO: design of an open label, single arm pilot study of OncoSil™ in subjects with unresectable locally advanced pancreatic adenocarcinoma, given in combination with standard chemotherapy. Ann Oncol. 2017;28(Suppl 3):mdx261.227. Scholar
  21. 21.
    Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:1039–49. Scholar
  22. 22.
    Sampliner JE. Postoperative care of the pancreatic surgical patient: the role of the intensivist. Surg Clin N Am. 2001;81(3):637–45.CrossRefGoogle Scholar
  23. 23.
    Segelman J, Nygren JO. Best practice in major elective rectal/pelvic surgery: enhanced recovery after surgery (ERAS). Updates in surgery. 2017.Google Scholar
  24. 24.
    Smith HJ, Boitano TKL, Rushton T, Johnston MC, Leath CA, Straughn JM. Impact of enhanced recovery after surgery (ERAS) protocol on postoperative pain control in chronic narcotic users. Gynecol Oncol. 2018;149:19.CrossRefGoogle Scholar
  25. 25.
    Sutton JM, Kooby DA, Wilson GC, et al. J Gastrointest Surg. 2014;18:1575. Scholar
  26. 26.
    Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:8.Google Scholar
  27. 27.
    Thiele RH, Raghunathan K, Brudney CS, Lobo DN, Martin D, Senagore A, Cannesson M, Gan TJ, Mythen MMG, Shaw AD, Miller TE, For the Perioperative Quality Initiative (POQI) I Workgroup. American Society for Enhanced Recovery (ASER) and Perioperative Quality Initiative (POQI) joint consensus statement on perioperative fluid management within an enhanced recovery pathway for colorectal surgery. Perioper Med. 2016;5(1):1–15.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.The University of Texas, MD Anderson Cancer CenterHoustonUSA
  2. 2.University of Minnesota Nurse Anesthesia ProgramMinneapolisUSA

Section editors and affiliations

  • Garry Brydges
    • 1
  1. 1.Department of Anesthesiology Division of Anesthesia, Critical Care and Pain MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations